{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:42Z","timestamp":1784408862818,"version":"3.55.0"},"reference-count":8,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2025.2864","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:42:45Z","timestamp":1749012165000},"page":"1-4","source":"Crossref","is-referenced-by-count":1,"title":["Extended progression\u2011free survival after combination treatment with anlotinib and S\u20111 in refractory advanced esophageal cancer: A case report"],"prefix":"10.3892","volume":"23","author":[{"given":"Jinsong","family":"Yang","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"key20250714143303_b1-MCO-23-2-02864","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"key20250714143303_b2-MCO-23-2-02864","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): A multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20250714143303_b3-MCO-23-2-02864","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1002\/cncr.24480","article-title":"Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: A retrospective, single-institution study","volume":"115","author":"Granger","year":"2009","journal-title":"Cancer"},{"key":"key20250714143303_b4-MCO-23-2-02864","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: First global approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"issue":"120","key":"key20250714143303_b5-MCO-23-2-02864","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"key20250714143303_b6-MCO-23-2-02864","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/cam4.3771","article-title":"Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial","volume":"10","author":"Huang","year":"2021","journal-title":"Cancer Med"},{"key":"key20250714143303_b7-MCO-23-2-02864","first-page":"6578","article-title":"Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: A case report","volume":"12","author":"Yang","year":"2020","journal-title":"Am J Transl Res"},{"key":"key20250714143303_b8-MCO-23-2-02864","doi-asserted-by":"publisher","first-page":"e2130","DOI":"10.1002\/onco.13950","article-title":"Anlotinib combined with S-1 in third- or later-line stage IV non-small cell lung cancer treatment: A phase II clinical trial","volume":"26","author":"Xiang","year":"2021","journal-title":"Oncologist"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T11:33:08Z","timestamp":1752492788000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2025.2864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2025.2864","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]}}}